Distinct Patterns of DNA Damage Response and Apoptosis Correlate with Jak/Stat and PI3Kinase Response Profiles in Human Acute Myelogenous Leukemia

Abstract

BackgroundSingle cell network profiling (SCNP) utilizing flow cytometry measures alterations in intracellular signaling responses. Here SCNP was used to characterize Acute Myeloid Leukemia (AML) disease subtypes based on survival, DNA damage response and apoptosis pathways.Methodology and Principal FindingsThirty four diagnostic non-M3 AML samples from patients with known clinical outcome were treated with a panel of myeloid growth factors and cytokines, as well as with apoptosis-inducing agents. Analysis of induced Jak/Stat and PI3K pathway responses in blasts from individual patient samples identified subgroups with distinct signaling profiles that were not seen in the absence of a modulator. In vitro exposure of patient samples to etoposide, a DNA damaging agent, revealed three distinct “DNA damage response (DDR)/apoptosis” profiles: 1) AML blasts with a defective DDR and failure to undergo apoptosis; 2) AML blasts with proficient DDR and failure to undergo apoptosis; 3) AML blasts with proficiency in both DDR and apoptosis pathways. Notably, AML samples from clinical responders fell within the “DDR/apoptosis” proficient profile and, as well, had low PI3K and Jak/Stat signaling responses. In contrast, samples from clinical non responders had variable signaling profiles often with in vitro apoptotic failure and elevated PI3K pathway activity. Individual patient samples often harbored multiple, distinct, leukemia-associated cell populations identifiable by their surface marker expression, functional performance of signaling pathway in the face of cytokine or growth factor stimulation, as well as their response to apoptosis-inducing agents.Conclusions and SignificanceCharacterizing and tracking changes in intracellular pathway profiles in cell subpopulations both at baseline and under therapeutic pressure will likely have important clinical applications, potentially informing the selection of beneficial targeted agents, used either alone or in combination with chemotherapy.

Cancer stem cell definitions and terminology: the devil is in the details

“…However, depending on the type of neoplasm, persistent MRD may not necessarily argue against long-term disease-free survival. In AML, it has been reported that [94][95][96][97] . Conversely, in chronic phase CML, the persistence of a detectable (that is, substantial) population of primitive (presumably pre-malignant) CML stem cells is not predictive of relapse 98 .…”

AKT Signaling as a Novel Factor Associated with In Vitro Resistance of Human AML to Gemtuzumab Ozogamicin

“…SCNP assays were performed as described previously [24]. Briefly, aliquots of cryopreserved cells were thawed at 37°C, washed, resuspended in RPMI 1640/60% FBS, and mononuclear cells isolated via ficoll density gradient.…”

From single cells to deep phenotypes in cancer

“…It turns out that this information can be catalogued ( Fig. 1), used to create diagnostic predictors at the singlecell level [26][27][28][29]33 and mathematically mined to elucidate cell subsets and responses that correlate to orthologous or surrogate phenotypes. Other correlates include clinical outcomes or drug response 34 , and reconstruction of cellular networks 32,35,36 .…”